Bladder

Explore a Clinical Trial for Bladder Cancer

Merck is passionate about improving health. We are committed to accelerating every step in the journey in our quest to bring treatment options to people with cancer.

Clinical trials for bladder cancer are underway and currently enrolling patients. If you have patients with bladder cancer, you may want to consider a Merck Oncology Clinical Trial. 

To see if your patients qualify for one of these trials, contact our clinical trial information center at 1-888-577-8839. If you are interested in partnering with us as an investigator, call 1-800-290-4339.

8

Active Trials

5

Trials Recruiting

81

US Trial Locations

Explore Active Clinical Trials

Trial Description Trial Number Condition Phase Status
Study of First-line Pembrolizumab With Lenvatinib in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy
7902-011 Urothelial Carcinoma Phase 3 Recruiting
Study of Pembrolizumab in Participants With High Risk Non-muscle Invasive Bladder Cancer
057 Bladder Cancer Phase 2 Recruiting
Efficacy and Safety of Pembrolizumab in Combination With Bacillus Calmette-Guerin in High-Risk Non-Muscle Invasive Bladder Cancer
676 High-risk Non-muscle Invasive Bladder Cancer Phase 3 Recruiting
Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer
866 Urinary Bladder Cancer, Muscle-invasive Phase 3 Recruiting
Perioperative Pembrolizumab Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer
905 Urinary Bladder Cancer, Muscle-invasive Phase 3 Recruiting
A Study of Pembrolizumab Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer
045 Urothelial Cancer Phase 3 Active, not recruiting
Study of Pembrolizumab in Participants With Advanced Urothelial Cancer
052 Urothelial Cancer Phase 2 Active, not recruiting
Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma
361 Urothelial Carcinoma Associated 1 RNA, Human Phase 3 Active, not recruiting